Short term correlates of the Neuro Emotional Technique for cancer-related traumatic stress symptoms: A pilot case series

Introduction As many as one quarter of all cancer survivors report traumatic stress symptoms from cancer-related experiences. While the majority of these patients do not meet the criteria for posttraumatic stress disorder (PTSD), there is growing evidence that subsyndromal symptoms can significantly contribute to functional impairment and negative health outcomes. Treatment options for the hallmark symptoms of traumatic stress—unpleasant, intrusive thoughts and avoidant behaviors—have not been well investigated for the cancer survivorship population. Materials and methods Seven female cancer survivors with traumatic stress symptoms from cancer-related experiences and no other major psychopathology, were enrolled to receive three sessions of Neuro-Emotional Technique (NET), a brief, targeted treatment that combines traditional desensitization principles with complementary modalities. Results Psychological outcome measures (Impact of Event Scale (IES) and Subjective Units of Distress (SUD) and physiological measures (Heart Rate (HR) and Skin Conductance Level (SCL) demonstrated the following changes: 71% on IES, 88% SUD, 74% on HR, and 65% on SCL following the intervention. Statistically significant changes were observed for all four parameters, and effect size g for proportion improved were 0.50 each for IES, SUD, and HR, and 0.20 for SCL. Conclusions These cases suggest feasibility of the NET intervention for cancer-related traumatic stress and the potential for change in symptoms and physiological reactivity. Further investigation is needed to determine the specific and long-term effects of such an approach. Implications for cancer survivors Traumatic stress from cancer-related experiences might represent a constellation of symptoms that are amenable to brief, targeted interventions. This study was supported by the O.N.E. Research Foundation     

医院网上预约挂号系统

目前，门诊一直是困扰医院提高服务质量的一个复杂环节，特别是医疗水平高、门诊量大的医院，门诊质量难以提高。此外，病人到医院就诊前对医院的相关信息了解不多，对所要挂的专科医生的情况又不太了解，具有较大的盲目性。随着互联网络的迅猛发展．我院的网站利用ASP技术以及ActiveX组件实现了网上预约挂号功能，用户可在网上通过浏览器很方便地查看医院介绍、专家、专科等具体的信息，通过这些措施可以正确引导病人选择所需的专家、专科或针对性强的医疗服务，提高医院门诊服务质量，为广大群众的就医提供了方便，取得良好的社会效益和经济效益。     

Isolation and partial characterization of the tegumental outer membrane of schistosomula of Schistosoma mansoni

Separation of the external membranes from freshly converted mechanical schistosomula of Schistosoma mansoni was achieved by osmotic shock under hypertonic conditions, followed by mechanical shearing and ultracentrifugation. Prior to treatment, the schistosomula were surface labeled by introduction of N-DNP-epsilon-aminocaproylphosphatidylethanolamine molecules into their lipid bilayer followed by anti-DNP antibodies and stained with either 125I-protein-A or ferritin labeled secondary anti-DNP antibodies. This label provided a membrane marker by which the purity of the preparation could be assessed at each stage. Fluorescence staining with FITC-conjugated secondary antibodies prior to treatment revealed that the homogeneously stained membrane of the intact schistosomula became swollen and ruptured after the osmotic shock. The isolated membrane pellet was intensely fluorescent. Electron microscopical examination revealed mostly vesicles, some of them with organized multilayer assembly. The vesicles were ferritin labeled, indicating that they originated from the outer surface membrane of the schistosomula. A 100 fold enrichment in the alkaline phosphatase activity and about 300 fold enrichment in acetylcholinesterase activity in the membrane preparations, as compared to the intact schistosomula, was found. The isolated tegument was analyzed by SDS-polyacrylamide gel electrophoresis. The pattern obtained showed three major bands, of molecular weights 69 000, 45 000 and 12 000 alongside with a large number of minor bands. Immunoprecipitation of the isolated 125I-labeled membrane antigens with antisera from chronically infected mice revealed these three major bands together with three other bands of molecular weight 38 000, 23 000 and 16 000.     

基于网络的在线调查统计系统的分析与实现

阐述了在线调查统计系统的体系结构和具体实现方法,解决了动态选择调查主题和以图表形式显示调查结果等难点并给出在线调查误差控制的方法。     

当归多糖对血瘀证动物免疫功能和抗氧化功能的影响

 目的：研究当归多糖(angelica polysaccharide,ASP)对血瘀证大鼠的影响。方法：采用阿霉素造大鼠血瘀证模型，观察当归多糖对血瘀证动物免疫功能和抗氧化功能的作用。结果：当归多糖可明显改善血瘀证大鼠免疫功能, 其胸腺指数和脾脏指数明显升高，免疫球蛋白IgG、IgM、补体C5含量明显升高，升高心、脑、肾、胰四脏器超氧化物歧化酶(SOD)活性，降低心、脑、肾、胰四脏器丙二醛(MDA)含量（P<0.05或P<0.01）。结论：当归多糖具有抗氧化效应和免疫促进效应。     

FLT3突变急性淋巴细胞白血病的临床特征

目的：探讨急性淋巴细胞白血病（acute lymphoblastic leukemia,ALL）患者FLT3（Fms-like tyrosine kinase）基因内部串联重复（internal tandem duplication,ITD）与其ASP835（D835）突变（mutation in the tyrosine kinase domain,FLT3-TKD）的发生情况及临床意义。方法采用聚合酶链反应法（polymerase chain reaction, PCR）扩增产物,采用限制性酶切产物分析法分析初诊患者基因易突变区的突变情况。结果147例ALL患者中,11例（7.5%）存在FLT3突变。FLT3突变患者与无突变患者在年龄、性别、骨髓原始细胞计数和外周血原始细胞计数的比较均无统计学意义（均P＞0.05）。T细胞型ALL（T-ALL）患者中FLT3突变的发生率为17.2%,其他类型ALL患者中FLT3突变的发生率为5.1%,差异具有非常显著的统计学意义（P＜0.001）。结论 ALL患者存在FLT3突变,且T-ALL患者的FLT3突变率高于其他类型患者。     

急性重症胰腺炎继发感染的大黄复方免疫疗法的临床实验研究

目的：初步探讨大黄复方综合免疫疗法对ASP继发感染的治疗作用。方法：肠道菌群检测和免疫组化，放射免疫分析法研究了ANP模型肠道菌群变化和肠道局部免疫的变化，在此基础上进一步对严格按标准选入的ASP病人，采用中药大黄复方及微生态制剂综合疗法分别在临床表现，生化及血清内毒素，肠道局部免疫与细菌易位等方面进行对比研究。结果：ANP肠道膜菌群生物屏障受到破坏，G^-肠杆菌是急性重症胰腺炎内源性感染的主要原因菌，综合免疫疗法治疗后1周及2周的生化指标及血清内毒素水平降低均优于常规组，结论：初步表明综合疗法能减轻或消除ANP继发感染临床表现，缩短感染持续时间。     

美国医疗机构抗菌药物临床应用管理策略及对我国的启示

抗菌药物管理计划的制定与实施是国外医疗机构提高抗菌药物合理使用水平的重要措施。在Pubmed等数据库文件检索的基础上,以美国疾病控制与预防中心开发的抗菌药物应用管理机制为主要研究对象,对国外医院抗菌药物管理项目及其相关评价研究从两方面进行归纳阐述,包括宏观层面管理和抗菌药物临床使用的细节管理。旨在通过借鉴国外经验,对我国医疗机构抗菌药物管理实践与研究的发展提出建议。     

The ALK inhibitor ASP3026 eradicates NPM-ALK+ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model

NPM-ALK⁺ T-cell anaplastic large-cell lymphoma (ALCL) is an aggressive type of cancer. Standard treatment of NPM-ALK⁺ ALCL is CHOP polychemotherapy. Although patients initially respond favorably to CHOP, resistance, relapse, and death frequently occur. Recently, selective targeting of ALK has emerged as an alternative therapeutic strategy. ASP3026 is a second-generation ALK inhibitor that can overcome crizotinib resistance in non-small cell lung cancer, and is currently being evaluated in clinical trials of patients with ALK⁺ solid tumors. However, NPM-ALK⁺ ALCL patients are not included in these trials. We studied the effects of ASP3026 on NPM-ALK⁺ ALCL cell lines in vitro and on systemic lymphoma growth in vivo. ASP3026 decreased the viability, proliferation, and colony formation, as well as induced apoptotic cell death of NPM-ALK⁺ ALCL cells. In addition, ASP3026 significantly reduced the proliferation of 293T cells transfected with NPM-ALK mutants that are resistant to crizotinib and downregulated tyrosine phosphorylation of these mutants. Moreover, ASP3026 abrogated systemic NPM-ALK⁺ ALCL growth in mice. Importantly, the survival of ASP3026-treated mice was superior to that of control and CHOP-treated mice. Our data suggest that ASP3026 is an effective treatment for NPM-ALK⁺ ALCL, and support the enrollment of patients with this lymphoma in the ongoing clinical trials.     

Absorption,distribution, metabolism and excretion of novel phosphodiesterase type 4 inhibitor ASP3258 in rats

The potent and selective phosphodiesterase 4 inhibitor ASP3258 is a novel therapeutic agent for asthma and chronic obstructive pulmonary disease (COPD). After a single oral administration to rats, ASP3258 is rapidly absorbed with a bioavailability of 106%. In situ absorption data indicated that ASP3258 is mainly absorbed in the small intestine. Tissue distribution data after oral administration of ¹⁴C‐ASP3258 showed rapid and extensive distribution to various tissues. Excluding the gastrointestinal tract, the tissues with the highest concentrations were liver, heart and plasma. Liquid chromatography‐nuclear magnetic resonance spectroscopy data revealed that O‐glucuronidation of the carboxylic acid moiety of ASP3258 (formation of an acyl glucuronide) plays a key role in metabolism. No indication was found that the acyl glucuronide reacted with proteins in plasma or tissues. When ¹⁴C‐ASP3258 was orally administered to intact rats, urinary and fecal excretion accounted for 1.3% and 100.6% of the administered radioactivity, respectively. After a single oral administration of ¹⁴C‐ASP3258 to bile‐cannulated rats, urinary and biliary excretion accounted for 0.7% and 93.8% of the administered radioactivity, respectively. These findings suggest that fecal excretion via bile plays an important role in the elimination of ASP3258‐derived radioactivity. In vitro metabolic profiles were relatively similar among the species examined, suggesting that our findings in rats may help us to understand pharmacokinetics, efficacy and safety profiles in humans and other species. Copyright © 2014 John Wiley & Sons, Ltd.